X-Vax Technology, Inc. is a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Their research leads us to believe that the new approach they are taking could succeed in defeating herpes. They have created a herpes vaccine candidate called ∆gD-2 (delta gD-2) because it is based on an HSV-2 virus genetically deleted for glycoprotein D (gD-2). With it, they have been able to prevent infections caused by herpes type 1 (HSV-1) and type 2 (HSV-2) in multiple preclinical models—with encouraging results. The vaccine induces Fc receptor activating antibodies that mediate antibody-dependent cell-mediated killing (ADCK) as the primary mechanism of protection. ADCK is induced to flag infected cells for destruction by natural immune cells.